Sustainability & Climate

He helped land a Bible on the moon, but his final years were spent in state custody as his historic legacy became trapped in a bitter legal battle.

A seven-year investment in a Virginia apartment complex yields a 24% IRR, showcasing the power of patient capital and strategic renovations.

A landmark journal issue introduces a new framework for facial rejuvenation, moving beyond outdated norms to embrace individualized, culturally sensitive care.

After retiring $1.4M in toxic debt, QHSLab has secured fresh equity to scale its AI-driven primary care platform, marking a pivotal turnaround.

StimLabs secures FDA clearance for Theracor, the first-ever umbilical cord sheet device, offering new hope for patients with hard-to-heal chronic wounds.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

A chiropractor with millions of followers claims he can reverse dementia. As science eyes a breakthrough, we examine the hope, the hype, and the business.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

Verisk terminates its $2.35B AccuLynx acquisition after FTC delays, triggering a $1.5B debt redemption and a potential legal battle with the spurned firm.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

Fresh off a volatile IPO, Malaysian hotpot chain CCH Holdings plans a massive 2026 expansion. Can this small-cap company conquer the U.S. and Africa?

A critical labor dispute at Canada’s largest propane export terminal is over, but not before testing the resilience of a key global energy supply chain.

Following a strategic acquisition, Sonida Senior Living unveils a revitalized memory care community, blending high-tech safety with person-centered care.

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.

Chinese firm launches durable centrifuges for sub-zero climates and announces a major localization strategy to capture a multi-billion dollar market.

Chinese cloud firm Cloopen forms a special committee to eye a go-private deal from its own CEO, putting shareholder value and corporate governance in the spotlight.

A new partnership with logistics giant Uniphar will bring Zevra's breakthrough NPC therapy, MIPLYFFA, to patients in underserved regions worldwide.

Establishment Labs has submitted its innovative Motiva implants for FDA approval in reconstruction, promising a new era for post-mastectomy care.

Anfield Energy appoints financial expert Lubica Niemann as CFO, signaling a strategic move to manage NASDAQ compliance and its ambitious US uranium production goals.

Bluejay Diagnostics can now make 9 million sepsis tests. This manufacturing win is huge, but the real race for FDA approval has only just begun.